In the context of AR-independent prostate cancer, which usually emerges as a result of ARSI therapies, FGF signaling seems to play a pivotal role, where non-neuroendocrine AR-negative tumors rely on FGF and MAPK signaling to bypass AR requirements in prostate cancer (Figure 2B) [7]. Here, AR is linked to prostate carcinoma.